AMRI plant gains SafeBridge HPAPI certification

By Gareth Macdonald

- Last updated on GMT

AMRI’s plant in Rensselaer, New York gained SafeBridge potent compound certification this week after an effort that spokesperson Andrea Schulz said istestament to the firm's "willingness to go the extra mile”.

The certification programme, which has been achieved by only 10 organisations since its introduction in 1999, covers all aspects of potent compound production, from containment to operator training and safety.

Schulz told in-PharmaTechnologist that “AMRI made a significant contribution in time and resources to complete this outside expert review of our capabilities and systems as part of a commitment to ourselves and our customers that we are operating at the highest standard for state-of-the-art for HPAPI synthesis.

SafeBridge is recognized as world-renowned authority in this field and their opinion is well-respected and sought out by companies who are advancing high potency APIs into drug manufacture​.”

She predicted that demand for high potency active pharmaceutical ingredient (HPAPI) manufacture which, in common with the rest of the drug industry has slowed in the downturn, will “return to recent strong levels​” as the economy recovers.

Global API market

AMRI has made HPAPIs and considered them a core competency for more than 15 years according to Schulz, who rejected the idea that in recent times Western API makers have focused on this area of the market in the face of low-cost Asian competition.

She said that, from AMRI's perspective, “while Asian manufacturers have made pricing more competitive, our continued expansion in India, and in other locations worldwide, as established by our US-based operations, positions us to offer customers’ solutions from an extensive pool of technologies, resources and cost structures to competitively position AMRI in this growing industry.

We believe HPAPI synthesis and controlled substance manufacturing are a niche where AMRI can excel and we will continue to look for opportunities to expand our relationships for this challenging and valuable work​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars